Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, COVID-19 Pneumonia, Female Pattern Baldness, Male Pattern Baldness
Conditions
Keywords
Covid19, Androgenetic alopecia
Brief summary
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.
Detailed description
INTRODUCTION: An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Belonging to the family Beta-coronavirus, this virus can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Numerous cases of new onset of skin lesions in COVID-19 patients are spreading across the globe. There are also some reports of aggravation of prior skin disorders. While severe COVID-19 symptoms and high mortality primarily manifested in older adults specially adult males, this sexual dimorphism in the severity of COVID-19 patients predisposed possibly due to increased androgen levels particularly in males suffering from androgenetic alopecia (AGA) would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19. OBJECTIVE: Association of Androgenetic alopecia and severity of Coronavirus disease 2019 (COVID-19). PLACE OF STUDY: COVID-19 isolation unit of Jinnah postgraduate medical center (JPMC) Karachi, Sindh province, Pakistan. RESEARCH METHODOLOGY: This study will be conducted on patients admitted in COVID-19 isolation unit of JPMC Karachi. Permission from the institutional ethical review committee will be taken prior to conduction of study, demographic data and written informed consent will be taken from every patient. Sample size of study would be 300 hospitalized patients of COVID-19. Detailed history and examination of patients including be conducted in COVID-19 patients. Scoring of AGA be evaluated using Hamilton-Norwood scale (HNS) in men and Ludwig scale in female. Severity of the COVID-19 be measured by COVID severity score (A-DROP). Study is aimed to evaluate association of AGA and severity of COVID-19, frequency of AGA in covid 19 and whether the lung involvement correlates with the severity of AGA or whether the proportion of AGA is higher in intensive care/fatal COVID-19. DATA ANALYSIS: Data will be analysed using SPSS version 23 registered for Microsoft windows. Mean and standard deviation will be calculated for expression of quantitative variables like age, weight, duration of disease symptoms. Frequencies and percentages will be calculated for the qualitative variables like gender, co-morbidities, frequency and severity of AGA, disease outcome and AGA associated with severity of COVID-19. Effect modifiers like age, gender, weight, co-morbidities, duration of symptoms will be controlled through stratification. Post-stratification will be recalculated and chi-square test will be applied. P-value of \<0.05% will be considered as significant.
Interventions
None listed
Sponsors
Syeda Mahanum Ali
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
20 Years to 100 Years
Inclusion criteria
* Hospitalized patients of diagnosed covid-19 age \> 20years * with or without androgenetic alopecia * with or without comorbidities * irrespective of disease duration -
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Disease outcome during this 4 month duration of study. | Hospital disease outcome as mask, cannnula, ventilator or death in 300 subjects. Having 220 males and 80 Females |
| Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months | It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly. |
| Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months | It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly. |
| Androgenetic Alopecia Frequency in Participants. | Day 1 of admission | Frequency of Androgenetic alopecia in patients be noted. |
| Severity of Androgenetic Alopecia in Patients | Day 1 of admission | Severity of androgenetic alopecia be measured using Hamilton and norwood scale (HNS) less than 3 or 3-7. In females using ludwig scale: less than 2 or 2-3. Hamilton norwood score: Minimum value 1, maximum value 7. Ludwig score: minimum 0, maximum 3 Mild to moderate: HNS \<3/ Ludwig \<2 Severe: HNS 3-7/ ludwig 2-3 |
| 300 Participants Mean Age | Day 1 of admission | Age of the patient is very important to co-relate with disease outcome and severity of Androgenetic alopecia |
| Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months | Outcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death |
| Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months | Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation |
| Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months | Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Duration of COVID-19 | Day 1 of admission, till disease outcome in upto 4 months | Duration of symptoms patients experiencing from the onset of symptoms till outcome. |
| Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | Date of randomization until upto 4 months | Comorbidities in patients suffering from covid-19 is of great value as it affects disease outcome.number of patients suffrring from comorbidities eg: diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity. |
Countries
Pakistan
Participant flow
Recruitment details
300 participants at COVID-19 isolation unit jinnah postgraduate medical centre karachi.
Pre-assignment details
* 300 participants signed consent for participation. * 300 participants assigned for the study.
Participants by arm
| Arm | Count |
|---|---|
| 220 Hospitalized Male Participants Diagnosed Case of COVID-19. 220 hospitalized male Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death. | 220 |
| 80 Hospitalized Female Participants Diagnosed Case of COVID-19 80 hospitalized female Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death. | 80 |
| Total | 300 |
Baseline characteristics
| Characteristic | Total | 220 Hospitalized Male Participants Diagnosed Case of COVID-19. | 80 Hospitalized Female Participants Diagnosed Case of COVID-19 |
|---|---|---|---|
| Age, Continuous | 53.06 years STANDARD_DEVIATION 13.5 | 53.39 years STANDARD_DEVIATION 14.928 | 52.17 years STANDARD_DEVIATION 8.391 |
| Age, Customized >60 years | 80 Participants | 80 Participants | 00 Participants |
| Age, Customized Between 20 to 40 years | 70 Participants | 41 Participants | 29 Participants |
| Age, Customized Between >40 to 60 years | 150 Participants | 99 Participants | 51 Participants |
| Comorbidities Chronic kidney disease | 15 Participants | 10 Participants | 5 Participants |
| Comorbidities Diabetes mellitus | 52 Participants | 35 Participants | 17 Participants |
| Comorbidities Hypertension | 51 Participants | 34 Participants | 17 Participants |
| Comorbidities Ischemic heart disease | 16 Participants | 12 Participants | 4 Participants |
| Comorbidities Multiple comorbidities | 39 Participants | 20 Participants | 19 Participants |
| Comorbidities No comorbidity | 92 Participants | 82 Participants | 10 Participants |
| Comorbidities Obesity | 21 Participants | 15 Participants | 6 Participants |
| Comorbidities Smoking | 16 Participants | 14 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 00 Participants | 00 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 300 Participants | 220 Participants | 80 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 00 Participants | 00 Participants |
| Region of Enrollment Pakistan | 300 Participants | 220 Participants | 80 Participants |
| Sex: Female, Male Female | 80 Participants | 00 Participants | 80 Participants |
| Sex: Female, Male Male | 220 Participants | 220 Participants | 00 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 87 / 300 |
| other Total, other adverse events | 0 / 300 |
| serious Total, serious adverse events | 300 / 300 |
Outcome results
Primary
300 Participants Mean Age
Age of the patient is very important to co-relate with disease outcome and severity of Androgenetic alopecia
Time frame: Day 1 of admission
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | 300 Participants Mean Age | 53.06 years | Standard Deviation 13.495 |
Primary
Androgenetic Alopecia Frequency in Participants.
Frequency of Androgenetic alopecia in patients be noted.
Time frame: Day 1 of admission
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Androgenetic Alopecia Frequency in Participants. | With androgenetic alopecia | 209 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Androgenetic Alopecia Frequency in Participants. | Without androgenetic alopecia | 11 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Androgenetic Alopecia Frequency in Participants. | With androgenetic alopecia | 37 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Androgenetic Alopecia Frequency in Participants. | Without androgenetic alopecia | 43 Participants |
Primary
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.
Time frame: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: nasal cannula | 0 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: nasal cannula | 7 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs nasal cannula | 00 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: mask/bag | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: mask/bag | 8 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs mask/bag | 00 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: ventilator | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: ventilator | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs: ventilator | 00 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: death | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: death | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs: death | 00 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: death | 2 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: nasal cannula | 4 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: ventilator | 5 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: nasal cannula | 5 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: death | 1 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs nasal cannula | 00 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: ventilator | 9 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age 20-40yrs: mask/bag | 7 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs: death | 00 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >40-60yrs: mask/bag | 10 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs: ventilator | 00 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. | Age >60yrs mask/bag | 00 Participants |
Primary
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.
Time frame: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula Age 20-40yrs | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula age >40-60yrs | 10 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula age >60yrs | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age 20-40yrs | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age >40-60yrs | 5 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age >60yrs | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age 20-40yrs | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age >40-60yrs | 2 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age >60yr | 2 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age 20-40yrs | 0 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age >40-60yrs | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age >60yrs | 3 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age >40-60yrs | 32 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula Age 20-40yrs | 11 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age 20-40yrs | 3 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula age >40-60yrs | 27 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age 20-40yrs | 7 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Nasal cannula age >60yrs | 14 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age >40-60yrs | 14 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age 20-40yrs | 9 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Death age >60yrs | 34 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age >40-60yrs | 8 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Ventilator age >60yr | 8 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males | Mask/bag age >60yrs | 10 Participants |
Primary
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Outcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death
Time frame: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age 20-40years | 15 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age >40-60 years | 13 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age >60years | 13 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on Nasal cannula with age 20-40years | 15 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on nasal cannula with age >40-60 years | 37 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on nasal cannula with age >60years | 20 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age 20-40years | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age >40-60 years | 16 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age >60years | 10 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age 20-40 years | 7 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age >40-60 years | 33 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age >60years | 37 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age >40-60 years | 6 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age 20-40years | 10 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age 20-40years | 11 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age >40-60 years | 18 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age 20-40 years | 4 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on mask/bag with age >60years | 0 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age >40-60 years | 15 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on Nasal cannula with age 20-40years | 4 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants death with age >60years | 0 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on nasal cannula with age >40-60 years | 12 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on ventilator with age >60years | 0 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. | Participants on nasal cannula with age >60years | 0 Participants |
Primary
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation
Time frame: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on nasal cannula with HNS <3 | 20 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on nasal cannula with HNS 3-7 | 52 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on mask/bag with HNS <3 | 14 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on mask/bag with HNS 3-7 | 27 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on ventilator with HNS <3 | 5 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients on ventilator with HNS 3-7 | 25 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients death with HNS <3 | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males | Patients death with HNS 3-7 | 73 Participants |
p-value: 0Chi-squared
Primary
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation
Time frame: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on mask/bag with no androgenetic alopecia | 9 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on mask/bag with ludwig scale <2 | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on mask/bag with ludwig scale 2-3 | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on nasal cannula without androgenetic alopecia | 17 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on nasal cannula with ludwig scale <2 | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on nasal cannula with ludwig scale 2-3 | 8 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on ventilator with no androgenetic alopecia | 14 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on ventilator with ludwig scale <2 | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants on ventilator with ludwig scale 2-3 | 9 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants death with no androgenetic alopecia | 3 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants death with ludwig scale <2 | 0 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females | Female participants death with ludwig scale 2-3 | 7 Participants |
p-value: 0.081Chi-squared
Primary
Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females
Hospital disease outcome as mask, cannnula, ventilator or death in 300 subjects. Having 220 males and 80 Females
Time frame: Disease outcome during this 4 month duration of study.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Mask/bag | 41 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Nasal cannula | 72 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Ventilator usage | 30 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Death | 77 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Death | 10 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Mask/bag | 28 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Ventilator usage | 26 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females | Nasal cannula | 16 Participants |
Primary
Severity of Androgenetic Alopecia in Patients
Severity of androgenetic alopecia be measured using Hamilton and norwood scale (HNS) less than 3 or 3-7. In females using ludwig scale: less than 2 or 2-3. Hamilton norwood score: Minimum value 1, maximum value 7. Ludwig score: minimum 0, maximum 3 Mild to moderate: HNS \<3/ Ludwig \<2 Severe: HNS 3-7/ ludwig 2-3
Time frame: Day 1 of admission
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Severity of Androgenetic Alopecia in Patients | Mild to moderate | 43 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Severity of Androgenetic Alopecia in Patients | Severe | 177 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Severity of Androgenetic Alopecia in Patients | Mild to moderate | 9 Participants |
| 80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19 | Severity of Androgenetic Alopecia in Patients | Severe | 28 Participants |
Secondary
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
Comorbidities in patients suffering from covid-19 is of great value as it affects disease outcome.number of patients suffrring from comorbidities eg: diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity.
Time frame: Date of randomization until upto 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with no comorbidity | 29 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of smoking | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of ischemic heart disease | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of diabetes mellitus | 12 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of hypertension | 15 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of obesity | 8 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of chronic kidney disease | 5 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on nasal cannula with history of multiple comorbidities | 9 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with no comorbidity | 20 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | Participants on mask/bag with history of smoking | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with history of history of ischemic heart disease | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with history of diabetes mellitus | 15 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with history of hypertension | 8 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with obesity | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with history of chronic kidney disease | 4 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on mask/bag with history of multiple comorbidities | 9 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with no comorbidity | 17 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | Participants on Ventilator with history of smoking | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with history of ischemic heart disease | 2 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with history of diabetes mellitus | 7 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with history of hypertension | 10 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with history of obesity | 6 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on Ventilator with history of chronic kidney disease | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant on ventilator with history of multiple comorbidities | 12 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | Participants death with no comorbidity | 26 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history of smoking | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death: history of ischemic heart disease | 9 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history diabetes mellitus | 18 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history of hypertension | 18 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history of obesity | 1 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history of kidney disease | 5 Participants |
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants | participant death with history of multiple comorbidities | 9 Participants |
Secondary
Disease Duration of COVID-19
Duration of symptoms patients experiencing from the onset of symptoms till outcome.
Time frame: Day 1 of admission, till disease outcome in upto 4 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 220 Hospitalized Participants Diagnosed Case of COVID-19. | Disease Duration of COVID-19 | 11.79 Days | Standard Deviation 5.727 |